Physician profile
Wade Travis
NPI 1558452961
$2,491.89
in general payments reported to CMS, 2019-2025
30 companies · $558 in 2025
The $558 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $292 · 2021: $245 · 2022: $187 · 2023: $345 · 2024: $489 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $398.48 | 2019-2025 | Bexsero |
| Corium, LLC | $377.62 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $332.26 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $243.02 | 2019-2025 | Doc Band |
| Sanofi Pasteur INC. | $141.98 | 2019-2023 | |
| Tris Pharma INC | $122.64 | 2020-2025 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $104.84 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $104.37 | 2019-2025 | Gardasil 9, Vaxneuvance, Varivax |
| Pfizer INC. | $82.18 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $62.66 | 2025 | Qelbree |
| Kowa Pharmaceuticals America, INC. | $62.27 | 2025 | Zoryve |
| Alk-Abello, INC | $50.79 | 2025 | Neffy, Grastek, Odactra |
| Genentech USA, INC. | $36.66 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $33.45 | 2025 | Neffy |
| Seqirus USA INC | $29.80 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $27.17 | 2019 | |
| Acadia Pharmaceuticals INC | $26.39 | 2023 | Daybue |
| Biomarin Pharmaceutical INC. | $26.00 | 2025 | Voxzogo 1.2mg |
| Arbor Pharmaceuticals, INC. | $25.50 | 2019 | |
| Abbott Laboratories | $24.81 | 2025 | Id Now Instrument |
| Lnhc, INC | $24.04 | 2025 | Zelsuvmi |
| Kaleo, INC. | $23.29 | 2020 | |
| Cipher Pharmaceuticals US LLC | $21.27 | 2025 | Natroba, Spinosad |
| Verrica Pharmaceuticals INC. | $19.83 | 2024 | Ycanth |
| Takeda Pharmaceuticals U.S.A., INC. | $19.40 | 2021 | |
| Shire North American Group INC | $16.25 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.50 | 2025 | Jornay Pm |
| Amneal Pharmaceuticals LLC | $14.49 | 2019 | |
| Aytu Biopharma, INC. | $13.75 | 2020 | |
| Sobi, INC | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wade Travis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.